miR-140 and miR-196a as Potential Biomarkers in Breast Cancer Patients.


Journal

Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625

Informations de publication

Date de publication:
01 Jul 2020
Historique:
received: 07 10 2019
entrez: 27 7 2020
pubmed: 28 7 2020
medline: 7 4 2021
Statut: epublish

Résumé

MiR-140 and miR-196a were known to be correlated with cancer diagnosis and prognosis. The current study aimed at the analysis of miR-140 and miR-196a expression patterns and their clinical significance for breast cancer (BC) patients. Differentially expressed miR-140 and miR-196a were examined via quantitative PCR in 110 cases of BC and their adjacent non-tumor (ANT) tissues. The results indicated that miR-140 and miR-196a, respectively, notably decreased and increased expression in BC samples in comparison with ANT (p<0.001). Reduced miR-140 expression was also related to Lymph node metastasis (LNM, P= 0.023) and stage (P = 0.009). Additionally, Receiver Operating Characteristics (ROC) analysis illustrated that miR-140 had a significant diagnostic accuracy for stage and LNM of BC patients. We also discovered a strong negative correlation between miR-196a expression with histological grade (P = 0.038), LNM (P = 0.012) and stage (P = 0.001). Overall, exploring the miR-140 and miR-196a profiles not only can statistically different among BC and ANT samples, but it is also expected to become potential BC biomarkers.<br />.

Identifiants

pubmed: 32711415
doi: 10.31557/APJCP.2020.21.7.1913
pmc: PMC7573432
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
MIRN196 microRNA, human 0
MicroRNAs 0
Mirn140 microRNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1913-1918

Références

Oncol Rep. 2016 Oct;36(4):2329-38
pubmed: 27498787
Oncogene. 2014 May 15;33(20):2589-600
pubmed: 23752191
Biol Res. 2016 Sep 27;49(1):40
pubmed: 27678369
Diagn Cytopathol. 2016 May;44(5):442-9
pubmed: 26865409
Iran J Basic Med Sci. 2018 Nov;21(11):1167-1173
pubmed: 30483391
Br J Cancer. 2014 Mar 4;110(5):1260-8
pubmed: 24423924
World J Gastroenterol. 2009 May 7;15(17):2089-96
pubmed: 19418581
Int J Clin Exp Pathol. 2018 Sep 01;11(9):4579-4584
pubmed: 31949856
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
Nature. 2005 Jun 9;435(7043):834-8
pubmed: 15944708
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
BMC Cancer. 2012 Aug 09;12:348
pubmed: 22876840
Br J Cancer. 2016 Jan 19;114(2):125-33
pubmed: 26757262
Am J Pathol. 2016 Jul;186(7):1724-35
pubmed: 27338107
Int J Cancer. 2011 Sep 1;129(5):1064-74
pubmed: 21077158
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1342-1348
pubmed: 29170130
Br J Cancer. 2019 Mar;120(6):621-632
pubmed: 30783203
Mol Cancer. 2017 Aug 17;16(1):139
pubmed: 28818100
Drug Res (Stuttg). 2017 Sep;67(9):509-514
pubmed: 28628924
Nat Rev Drug Discov. 2017 Mar;16(3):203-222
pubmed: 28209991
Sci Rep. 2017 Apr 06;7:45915
pubmed: 28383568
Ther Adv Med Oncol. 2010 Mar;2(2):125-48
pubmed: 21789130
Cancer Gene Ther. 2017 Sep;24(9):386-392
pubmed: 28752859
Pancreas. 2012 Jul;41(5):671-7
pubmed: 22695087
Artif Cells Nanomed Biotechnol. 2017 Sep;45(6):1-6
pubmed: 27684298
Mol Cancer. 2018 Apr 23;17(1):83
pubmed: 29685157
Artif Cells Nanomed Biotechnol. 2016 Dec;44(8):1972-1978
pubmed: 26772615
Mol Med Rep. 2018 Sep;18(3):2866-2872
pubmed: 30015904
Clin Sci (Lond). 2015 Nov;129(10):863-73
pubmed: 26318829
Iran J Cancer Prev. 2016 Aug 16;9(4):e4190
pubmed: 27761206
Cancer Genet. 2015 Jun;208(6):289-302
pubmed: 26004033
Eur J Cancer. 2017 Feb;72:1-11
pubmed: 27997852
Mater Sci Eng C Mater Biol Appl. 2019 Nov;104:110007
pubmed: 31500008
J Cell Mol Med. 2011 Jan;15(1):14-23
pubmed: 21091634
Mol Ther Nucleic Acids. 2018 Mar 2;10:426-437
pubmed: 29499953
Oncol Lett. 2019 Apr;17(4):3835-3841
pubmed: 30881504
J Cell Physiol. 2019 Aug;234(8):12341-12352
pubmed: 30609026
PLoS One. 2013 Sep 10;8(9):e73604
pubmed: 24039995
Theranostics. 2015 Jul 13;5(10):1122-43
pubmed: 26199650
Asian Pac J Trop Med. 2016 Nov;9(11):1105-1110
pubmed: 27890373
Mol Cancer Ther. 2012 Apr;11(4):842-52
pubmed: 22343731
Curr Mol Med. 2019;20(1):13-35
pubmed: 31573884

Auteurs

Arman Shahabi (A)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Cell Therapy and Regenerative Medicine Comprehensive Center, Kerman University of Medical Sciences, Kerman, Iran.

Behrooz Naghili (B)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.

Khalil Ansarin (K)

Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Vahid Montazeri (V)

Department of Thoracic Surgery, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Nosratollah Zarghami (N)

Infectious and Tropical Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Department of Clinical Biochemistry and Laboratory Medicine, Faculty of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH